한글목차

리보핵산(RNA) 치료 임상시험 시장 규모는 최근 꾸준히 성장하고 있습니다. 2025년 27억 달러에서 2026년에는 28억 3,000만 달러에 이르고, CAGR 4.8%의 성장이 전망되고 있습니다. 지금까지의 성장은 제한된 수의 RNA 기반 치료 옵션, 초기 임상시험의 높은 비용, 규제 당국의 승인 문제, RNA 치료에 대한 낮은 인지도, 기존 치료법에 대한 의존도 등이 원인으로 작용한 것으로 보입니다.

리보핵산(RNA) 치료 임상시험 시장 규모는 향후 몇 년간 꾸준한 성장이 전망됩니다. 2030년에는 34억 달러에 이르고, CAGR은 4.7%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 RNA 전달 기술의 발전, 희귀질환 및 항암제 연구에 대한 자금 증가, 생명공학 기업과 제약 기업 간의 협력 강화, 개인 맞춤형 의료 접근법의 보급 확대, 세계 임상시험 네트워크의 확대 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 치료 영역 전반에 걸친 RNA 치료 임상시험 수 증가, 희귀질환 및 항암 RNA 치료제에 대한 관심 증가, mRNA 백신 및 자가증폭 RNA 치료 시험 확대, CRISPR 및 RNA 편집 기반 치료 시험 도입, 첨단 전달 플랫폼 및 올리고뉴클레오타이드 복합체 통합 등이 있습니다. 플랫폼과 올리고뉴클레오티드 복합체의 통합 등을 들 수 있습니다.

감염성 질환 증가 추세는 향후 몇 년 동안 리보핵산(RNA) 치료 임상시험 시장의 성장을 가속할 것으로 예측됩니다. 감염은 세균, 바이러스, 곰팡이, 기생충 등 병원성 미생물이 인체에 침입하여 증식하여 건강을 해치는 것을 말합니다. 감염증 증가는 주로 국제 이동 증가에 의해 촉진되고 있으며, 이로 인해 병원체가 지역과 집단을 넘어 빠르게 확산될 수 있습니다. RNA 치료제 임상시험은 신종 병원체에 신속하게 대응할 수 있는 표적치료제 개발 및 평가를 지원하여 감염병 대응에 기여합니다. 예를 들어, 2025년 4월 미네소타주 보건국은 35-39세 남성의 HIV 감염자 비율이 2023년 10%에서 2024년 17%로 증가했다고 보고했습니다. 따라서 감염성 질환 증가 부담은 RNA 치료 임상시험 시장을 주도하고 있습니다.

이 시장의 주요 기업들은 특정 유전자 서열을 표적으로 하여 유전자 발현을 조절하고 유전성 질환 및 희귀질환에 대한 정밀한 치료를 제공하는 RNA 기반 안티센스 올리고뉴클레오티드 치료 임상시험과 같은 혁신적인 접근 방식에 초점을 맞추었습니다. 예를 들어, 2024년 12월 프랑스에 본사를 둔 생명공학 기업 세풀 바이오는 망막색소변성증(RP) 및 어셔 증후군 2a형을 유발하는 USH2A 유전자의 엑손 13 돌연변이를 표적으로 하는 RNA 기반 항센스 올리고뉴클레오타이드 치료제인 '우르테브루센'을 평가하는 LUNA 2b상 임상시험을 개시했습니다. 2년 동안 진행되는 이번 이중맹검 무작위 위약대조 임상시험은 전 세계 여러 기관에서 8세 이상의 성인 및 소아 환자 81명을 등록할 예정입니다. 본 치료법은 시력, 망막 민감도, 망막 구조 개선에 대한 유망한 1/2상 시험 결과를 바탕으로 시행되는 치료법입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Ribonucleic acid (RNA) therapy clinical trials are research studies designed to assess the safety, efficacy, and optimal use of therapies that employ RNA-based molecules to treat or prevent diseases. These trials aim to develop innovative interventions that work by modulating gene expression, correcting genetic defects, or enabling the body to produce beneficial proteins to address various medical conditions.

The main modalities in RNA therapy clinical trials include RNA interference, antisense therapy, messenger RNA (mRNA), oligonucleotides, non-antisense therapies, and non-RNA interference (RNAi) approaches. RNA interference is a natural cellular process in which small RNA molecules inhibit gene expression or translation by neutralizing specific messenger RNA molecules. These trials span multiple clinical phases, including phase I, phase II, phase III, and phase IV, and cover a wide range of therapeutic areas, such as rare diseases, anti-infectives, oncology, neurological disorders, metabolic and alimentary conditions, musculoskeletal disorders, cardiovascular and respiratory diseases, sensory disorders, and others.

Tariffs have impacted the RNA therapy clinical trials market by increasing the cost of imported nucleotides, reagents, and specialized laboratory equipment. Segments like mRNA-based vaccine trials, RNAi therapy trials, and oligonucleotide trials are most affected, particularly in North America and Europe where imports are significant. This has led to higher operational costs and potential delays in trial initiation. On the positive side, tariffs have encouraged local sourcing, investment in domestic research infrastructure, and innovation in cost-effective RNA therapy platforms.

The ribonucleic acid (rna) therapy clinical trials market research report is one of a series of new reports from The Business Research Company that provides ribonucleic acid (rna) therapy clinical trials market statistics, including ribonucleic acid (rna) therapy clinical trials industry global market size, regional shares, competitors with a ribonucleic acid (rna) therapy clinical trials market share, detailed ribonucleic acid (rna) therapy clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid (rna) therapy clinical trials industry. This ribonucleic acid (rna) therapy clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ribonucleic acid (rna) therapy clinical trials market size has grown steadily in recent years. It will grow from $2.7 billion in 2025 to $2.83 billion in 2026 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to limited rna-based therapeutic options, high cost of early-stage clinical trials, regulatory approval challenges, low awareness of rna therapies, reliance on traditional therapeutic modalities.

The ribonucleic acid (rna) therapy clinical trials market size is expected to see steady growth in the next few years. It will grow to $3.4 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to advancements in rna delivery technologies, increasing funding for rare disease and anticancer research, growing collaboration between biotech and pharma companies, rising adoption of personalized medicine approaches, expansion of global clinical trial networks. Major trends in the forecast period include increasing number of rna therapy clinical trials across therapeutic areas, growing focus on rare disease and anticancer rna therapeutics, expansion of mrna vaccine and self-amplifying rna therapy trials, adoption of crispr and rna editing-based therapy trials, integration of advanced delivery platforms and oligonucleotide conjugates.

The increasing burden of infectious diseases is expected to drive the growth of the ribonucleic acid (RNA) therapy clinical trials market in the coming years. Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites that invade the body, multiply, and compromise health. The rise in infectious diseases is largely fueled by increased global travel, which facilitates the rapid spread of pathogens across regions and populations. RNA therapy clinical trials aid in combating infectious diseases by supporting the development and evaluation of targeted treatments that can adapt quickly to emerging pathogens. For instance, in April 2025, the Minnesota Department of Health reported that the proportion of HIV cases among males aged 35 to 39 increased from 10% in 2023 to 17% in 2024. Therefore, the growing burden of infectious diseases is propelling the RNA therapy clinical trials market.

Key companies in this market are focusing on innovative approaches, such as RNA-based antisense oligonucleotide therapy clinical trials, which target specific genetic sequences to modulate gene expression and provide precise treatments for genetic and rare diseases. For example, in December 2024, Sepul Bio, a France-based biotechnology company, initiated the LUNA Phase 2b clinical trial to evaluate ultevursen, an RNA-based antisense oligonucleotide therapy targeting exon 13 mutations of the USH2A gene, which cause retinitis pigmentosa (RP) and Usher syndrome type 2a. This two-year, double-masked, randomized, sham-controlled study will enroll 81 adults and children aged eight and above across multiple global sites. The therapy follows promising Phase 1/2 results demonstrating improvements in visual acuity, retinal sensitivity, and retinal structure.

In July 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired DTx Pharma for $1 billion. Through this acquisition, Novartis strengthened its neuroscience pipeline and expanded capabilities in RNA-based therapeutics by integrating DTx Pharma's FALCON platform and advancing small interfering RNA (siRNA) programs for neuromuscular and neurological disorders. DTx Pharma is a US-based company specializing in RNA-based therapeutics clinical trials for neuromuscular and neurological conditions.

Major companies operating in the ribonucleic acid (rna) therapy clinical trials market are Pfizer Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., BioNTech SE, Biogen Inc., Daiichi Sankyo Company Limited, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Cartesian Therapeutics Inc., CureVac N.V., Orna Therapeutics Inc., Silence Therapeutics plc, ETHRIS GmbH, ProQR Therapeutics N.V., Lexeo Therapeutics Inc., Avidity Biosciences Inc., Aro Biotherapeutics Company, Wave Life Sciences Ltd.

North America was the largest region in the ribonucleic acid (RNA) therapy clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna) therapy clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ribonucleic acid (rna) therapy clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ribonucleic acid (RNA) therapy clinical trials market includes revenues earned by entities by providing services, such as RNA therapeutic administration, biological sample collection and analysis, long-term follow-up, genetic and molecular testing, and patient screening and enrollment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ribonucleic Acid (RNA) Therapy Clinical Trials Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses ribonucleic acid (rna) therapy clinical trials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ribonucleic acid (rna) therapy clinical trials ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ribonucleic acid (rna) therapy clinical trials market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Modality: Ribonucleic Acid (RNA) Interference; Antisense Therapy; Messenger Ribonucleic Acid (RNA); Oligonucleotide; Non-Antisense; Non-Ribonucleic Acid Interference (RNAi)
• 2) By Clinical Trials Phase: Phase I; Phase II; Phase III; Phase IV
• 3) By Therapeutic Areas: Rare Diseases; Anti-Infective; Anticancer; Neurological; Alimentary Or Metabolic; Musculoskeletal; Cardiovascular Respiratory; Sensory; Other Therapeutic Areas
• Subsegments:
• 1) By Ribonucleic Acid (RNA) Interference: Small Interfering RNA (siRNA) Therapy Trials; MicroRNA (miRNA)-Based Therapy Trials; Short Hairpin RNA (shRNA) Therapy Trials; Dicer Substrate RNA Therapy Trials
• 2) By Antisense Therapy: Gapmer Antisense Oligonucleotide Trials; Steric Blocking Antisense Trials; Splice-Switching Antisense Oligonucleotide Trials; Antisense Oligonucleotide-Conjugated Delivery Trials
• 3) By Messenger Ribonucleic Acid (RNA): mRNA-Based Vaccines Trials; Self-Amplifying mRNA (saRNA) Therapy Trials; Non-Replicating mRNA Therapy Trials; Circular mRNA Therapy Trials
• 4) By Oligonucleotide: Phosphorothioate Oligonucleotide Trials; Peptide Nucleic Acid (PNA) Trials; Locked Nucleic Acid (LNA) Trials; Morpholino Oligonucleotide Trials
• 5) By Non-Antisense: RNA Aptamer Therapy Trials; Guide RNA (gRNA)-Mediated CRISPR Trials; RNA Editing Therapy Trials; RNA Scaffolding Or Regulatory RNA Therapy Trials
• 6) By Non-Ribonucleic Acid Interference (RNAi): Ribozymes Therapy Trials; RNA Decoys Or Sponge RNA Trials; Long Non-Coding RNA (lncRNA) Therapy Trials; Small Activating RNA (saRNA) Therapy Trials
• Companies Mentioned: Pfizer Inc.; AstraZeneca plc; Novartis AG; GlaxoSmithKline plc; Moderna Inc.; BioNTech SE; Biogen Inc.; Daiichi Sankyo Company Limited; Alnylam Pharmaceuticals Inc.; Sarepta Therapeutics Inc.; Ionis Pharmaceuticals Inc.; Arrowhead Pharmaceuticals Inc.; Arcturus Therapeutics Holdings Inc.; Cartesian Therapeutics Inc.; CureVac N.V.; Orna Therapeutics Inc.; Silence Therapeutics plc; ETHRIS GmbH; ProQR Therapeutics N.V.; Lexeo Therapeutics Inc.; Avidity Biosciences Inc.; Aro Biotherapeutics Company; Wave Life Sciences Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Ribonucleic Acid (RNA) Therapy Clinical Trials Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Ribonucleic Acid (RNA) Therapy Clinical Trials Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Increasing Number Of RNA Therapy Clinical Trials Across Therapeutic Areas
  • 4.2.2 Growing Focus On Rare Disease And Anticancer RNA Therapeutics
  • 4.2.3 Expansion Of mRNA Vaccine And Self-Amplifying RNA Therapy Trials
  • 4.2.4 Adoption Of CRISPR And RNA Editing-Based Therapy Trials
  • 4.2.5 Integration Of Advanced Delivery Platforms And Oligonucleotide Conjugates

5. Ribonucleic Acid (RNA) Therapy Clinical Trials Market Analysis Of End Use Industries

• 5.1 Biotechnology Companies
• 5.2 Pharmaceutical Companies
• 5.3 Academic Research Institutes
• 5.4 Contract Research Organizations (CROs)
• 5.5 Clinical Trial Centers

6. Ribonucleic Acid (RNA) Therapy Clinical Trials Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Ribonucleic Acid (RNA) Therapy Clinical Trials PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Ribonucleic Acid (RNA) Therapy Clinical Trials Market Segmentation

• 9.1. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ribonucleic Acid (RNA) Interference, Antisense Therapy, Messenger Ribonucleic Acid (RNA), Oligonucleotide, Non-Antisense, Non-Ribonucleic Acid Interference (RNAi)
• 9.2. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Clinical Trials Phase, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Phase I, Phase II, Phase III, Phase IV
• 9.3. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Rare Diseases, Anti-Infective, Anticancer, Neurological, Alimentary Or Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Other Therapeutic Areas
• 9.4. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Sub-Segmentation Of Ribonucleic Acid (RNA) Interference, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Small Interfering RNA (siRNA) Therapy Trials, MicroRNA (miRNA)-Based Therapy Trials, Short Hairpin RNA (shRNA) Therapy Trials, Dicer Substrate RNA Therapy Trials
• 9.5. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Sub-Segmentation Of Antisense Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Gapmer Antisense Oligonucleotide Trials, Steric Blocking Antisense Trials, Splice-Switching Antisense Oligonucleotide Trials, Antisense Oligonucleotide-Conjugated Delivery Trials
• 9.6. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Sub-Segmentation Of Messenger Ribonucleic Acid (RNA), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• mRNA-Based Vaccines Trials, Self-Amplifying mRNA (saRNA) Therapy Trials, Non-Replicating mRNA Therapy Trials, Circular mRNA Therapy Trials
• 9.7. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Sub-Segmentation Of Oligonucleotide, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Phosphorothioate Oligonucleotide Trials, Peptide Nucleic Acid (PNA) Trials, Locked Nucleic Acid (LNA) Trials, Morpholino Oligonucleotide Trials
• 9.8. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Sub-Segmentation Of Non-Antisense, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• RNA Aptamer Therapy Trials, Guide RNA (gRNA)-Mediated CRISPR Trials, RNA Editing Therapy Trials, RNA Scaffolding Or Regulatory RNA Therapy Trials
• 9.9. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Sub-Segmentation Of Non-Ribonucleic Acid Interference (RNAi), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Ribozymes Therapy Trials, RNA Decoys Or Sponge RNA Trials, Long Non-Coding RNA (lncRNA) Therapy Trials, Small Activating RNA (saRNA) Therapy Trials

10. Ribonucleic Acid (RNA) Therapy Clinical Trials Market Regional And Country Analysis

• 10.1. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 11.1. Asia-Pacific Ribonucleic Acid (RNA) Therapy Clinical Trials Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 12.1. China Ribonucleic Acid (RNA) Therapy Clinical Trials Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 13.1. India Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 14.1. Japan Ribonucleic Acid (RNA) Therapy Clinical Trials Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 15.1. Australia Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 16.1. Indonesia Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 17.1. South Korea Ribonucleic Acid (RNA) Therapy Clinical Trials Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 18.1. Taiwan Ribonucleic Acid (RNA) Therapy Clinical Trials Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 19.1. South East Asia Ribonucleic Acid (RNA) Therapy Clinical Trials Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 20.1. Western Europe Ribonucleic Acid (RNA) Therapy Clinical Trials Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 21.1. UK Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 22.1. Germany Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 23.1. France Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 24.1. Italy Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 25.1. Spain Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 26.1. Eastern Europe Ribonucleic Acid (RNA) Therapy Clinical Trials Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 27.1. Russia Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 28.1. North America Ribonucleic Acid (RNA) Therapy Clinical Trials Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 29.1. USA Ribonucleic Acid (RNA) Therapy Clinical Trials Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 30.1. Canada Ribonucleic Acid (RNA) Therapy Clinical Trials Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 31.1. South America Ribonucleic Acid (RNA) Therapy Clinical Trials Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 32.1. Brazil Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 33.1. Middle East Ribonucleic Acid (RNA) Therapy Clinical Trials Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Ribonucleic Acid (RNA) Therapy Clinical Trials Market

• 34.1. Africa Ribonucleic Acid (RNA) Therapy Clinical Trials Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Ribonucleic Acid (RNA) Therapy Clinical Trials Market, Segmentation By Modality, Segmentation By Clinical Trials Phase, Segmentation By Therapeutic Areas, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Ribonucleic Acid (RNA) Therapy Clinical Trials Market Regulatory and Investment Landscape

36. Ribonucleic Acid (RNA) Therapy Clinical Trials Market Competitive Landscape And Company Profiles

• 36.1. Ribonucleic Acid (RNA) Therapy Clinical Trials Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Ribonucleic Acid (RNA) Therapy Clinical Trials Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Ribonucleic Acid (RNA) Therapy Clinical Trials Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Ribonucleic Acid (RNA) Therapy Clinical Trials Market Other Major And Innovative Companies

• BioNTech SE, Biogen Inc., Daiichi Sankyo Company Limited, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Cartesian Therapeutics Inc., CureVac N.V., Orna Therapeutics Inc., Silence Therapeutics plc, ETHRIS GmbH, ProQR Therapeutics N.V., Lexeo Therapeutics Inc.

38. Global Ribonucleic Acid (RNA) Therapy Clinical Trials Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Ribonucleic Acid (RNA) Therapy Clinical Trials Market

40. Ribonucleic Acid (RNA) Therapy Clinical Trials Market High Potential Countries, Segments and Strategies

• 40.1 Ribonucleic Acid (RNA) Therapy Clinical Trials Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Ribonucleic Acid (RNA) Therapy Clinical Trials Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Ribonucleic Acid (RNA) Therapy Clinical Trials Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer